Advanced search
Publication Cover
Bioengineered Volume 12, 2021 - Issue 1
Submit an article Journal homepage
1,631
Views
4
CrossRef citations to date
0
Altmetric
Research Paper

Mesenchymal stem cells (MSC) delays the occurrence of graft-versus-host disease(GVHD) in the inhibition of hematopoietic stem cells in major histocompatibility complex semi-consistent mice by regulating the expression of IFN-γ/IL-6

Ying WangDepartment of Hematology, the Seventh Affiliated Hopital, Sun Yat-sen University, Shenzhen, ChinaCorrespondence[email protected]
Pages 4500-4507 | Received 07 Jun 2021, Accepted 09 Jul 2021, Published online: 24 Jul 2021

References

  • Hülsdünker J, Zeiser R. Insights into the pathogenesis of GVHD: what mice can teach us about man. Hla. 2016;85(1):2–9.
  • Shono Y, Docampo MD, Peled JU. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med. 2016;8(339):339ra71–339ra71.
  • Matta BM, Reichenbach DK, Peri-allohct ZX. IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood. 2016;128(3):427–439.
  • Keklik F, Cayci Z, Arndt P. Spontaneous complete resolution of pneumomediastinum and pneumatosis intestinalis caused by acute GVHD. Am J Hematol. 2016;91(7):749–750.
  • Rapoport Y, Freeman T, Koyama T. Validation of international chronic ocular graft-versus-host disease (GVHD) group diagnostic criteria as a chronic ocular GVHD-specific metric. Cornea. 2017;36(2):258–263.
  • Parody R, Sureda A. Mesenchymal stromal cells for steroid-refractory acute GVHD. Lancet Haematol. 2016;3(1):e8–e9. .
  • Leclerc M, Naserian S, Pilon C. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells. Blood. 2016;128(12):1651–1659.
  • Cutler CS, Koreth J, Ritz J. Mechanistic approaches for the prevention and treatment of chronic GVHD. Blood. 2017;129(1):22–29.
  • Lu Y, Hippen KL, Lemire AL. miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. Blood. 2016;128(10):1424.
  • Pierini A, Strober WA, Moffett C. TNF-alpha priming enhances CD4+FoxP3+ regulatory T cell suppressive function in GVHD prevention and treatment. Biol Blood Marrow Transplant. 2016;22(3):S144–S145. .
  • Mcdonald-Hyman C, Flynn R, Panoskaltsis-Mortari A. Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood. 2016;128(7):1013–1017.
  • Marsh RA, Neumeier L, Mehta PA. Peri-transplant alemtuzumab levels IMPACT ACUTE GVHD, MIXED chimerism, and lymphocyte recovery following reduced intensity conditioning with alemtuzumab, fludarabine, and melphalan. Biol Blood Marrow Transplant. 2016;22(3):S337. .
  • Peled JU, Hanash AM, Jenq RR. Role of the intestinal mucosa in acute gastrointestinal GVHD. Blood. 2016;128(20):2395–2402.
  • Anwer F, Shaukat AA, Zahid U. Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. Immunotherapy. 2017;9(2):123–130.
  • Malard F, Labopin M, Chevallier P. Larger number of invariant natural killer T cells in PBSC allografts is associated with improved GVHD-free, progression-free survival. Blood. 2016;127(14):1828.
  • Heinrichs J, Li J, Nguyen H. CD8+ Tregs promote GVHD prevention and overcome the impaired GVL effect mediated by CD4+ Tregs in mice. Onco Immunol. 2016;5(6).
  • Salmenniemi U, ItäläRemes M, Nystedt J. Good responses but high TRM in adult patients after MSC therapy for GVHD. Bone Marrow Transplant. 2016;52(4):606.
  • Koichi M. Insurance approval of mesenchymal stem cell for acute GVHD in Japan: need of follow up for some remaining concerns. Int J Hematol. 2016;103(2):155–164.
  • Rotz SJ, Dandoy CE, Davies SM. ST2 and endothelial injury as a link between GVHD and microangiopathy. N Engl J Med. 2017;376(12):1189–1190.
  • Tang B, Ren H, Liu H. CCR5 blockade combined with cyclosporine A attenuates liver GVHD by impairing T cells function. Inflammation Res. 2016;65(11):917–924.
  • Mori S, Ahmed W, Patel RD. Steroid refractory acute liver GVHD in a Hodgkin\”s patient after allogeneic stem transplant cell transplantation following treatment with anti PD-1 antibody, nivolumab, for relapsed disease. Biol Blood Marrow Transplant. 2016;22(3):S392–S393. .
  • Bunting MD, Varelias A, Souza-Fonseca-Guimaraes F. GVHD prevents NK-cell–dependent leukemia and virus-specific innate immunity. Blood. 2017;129(5):630–642.
  • Zhang C, Bai N, Huang W. The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays. Ann Hematol. 2016;95(11):1833–1843.
  • Matsukuma KE, Wei D, Sun K. Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD). J Gastrointest Oncol. 2016;7(Suppl 1):S21–31.
  • Leveque-El ML, Koyama M, Le TL. Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD. Blood. 2016;128(6):794–804.
  • Gori JL, Scott Mcivor R, Kaufman D. Methotrexate supports in vivo selection of human embryonic stem cell derived-hematopoietic cells expressing dihydrofolate reductase. Bioengineered Bugs. 2010;1(6):434–436.
  • Zhang C, Liu J, Guo H, et al. m6A RNA methylation regulators were associated with the malignancy and prognosis of ovarian cancer. Bioengineered. 2021;12(1):1,3159–3176.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.